Daniel M. Geynisman
About
Daniel M. Geynisman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery.
According to data from OpenAlex, Daniel M. Geynisman has authored 174 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Pulmonary and Respiratory Medicine, 68 papers in Oncology and 62 papers in Surgery. Recurrent topics in Daniel M. Geynisman's work include Bladder and Urothelial Cancer Treatments (55 papers), Renal cell carcinoma treatment (51 papers) and Cancer Immunotherapy and Biomarkers (38 papers). Daniel M. Geynisman is often cited by papers focused on Bladder and Urothelial Cancer Treatments (55 papers), Renal cell carcinoma treatment (51 papers) and Cancer Immunotherapy and Biomarkers (38 papers). Daniel M. Geynisman collaborates with scholars based in United States, Spain and Italy. Daniel M. Geynisman's co-authors include Elizabeth R. Plimack, Matthew R. Zibelman, Ya‐Chen Tina Shih, Elizabeth A. Handorf, Robert G. Uzzo, Pooja Ghatalia, Fabrice Smieliauskas, Karen E. Wickersham, Alexander Kutikov and Yu‐Ning Wong and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Journal of Clinical Oncology.
In The Last Decade
Daniel M. Geynisman
160 papers receiving 2.5k citations
Peers
Daniel M. Geynisman
Efrat Dotan United States
Brian A. Costello United States
Arya Amini United States
Jamie Ritchey United States
Scott Ernst Canada
Thenappan Chandrasekar United States
Matthew A. Powell United States
D. Hölzel Germany
A. Karim Kader United States
Björn Tavelin Sweden
Citations per year, relative to Daniel M. Geynisman Daniel M. Geynisman (= 1×)
peers
Efrat Dotan
Countries citing papers authored by Daniel M. Geynisman
Since
Specialization
Citations
This map shows the geographic impact of Daniel M. Geynisman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel M. Geynisman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel M. Geynisman more than expected).
Fields of papers citing papers by Daniel M. Geynisman
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Daniel M. Geynisman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel M. Geynisman. The network helps show where Daniel M. Geynisman may publish in the future.
Co-authorship network of co-authors of Daniel M. Geynisman
This figure shows the co-authorship network connecting the top 25 collaborators of Daniel M. Geynisman. A scholar is included among the top collaborators of Daniel M. Geynisman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel M. Geynisman. Daniel M. Geynisman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ghatalia, Pooja, Eric A. Ross, Matthew R. Zibelman, et al.. (2025). A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2).. Journal of Clinical Oncology. 43(5_suppl). 815–815.
2.
Kaur, Jasmeet, et al.. (2025). Comparison of Outcomes Between African American and European American Patients With Metastatic Clear Cell Renal Cell Carcinoma Receiving Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer. 23(2). 102304–102304.
3.
Geynisman, Daniel M., Kateryna Chepynoga, Ashley Tate, et al.. (2025). Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase 3 CheckMate 274 Trial. Clinical Genitourinary Cancer. 23(3). 102335–102335.
4.
Geynisman, Daniel M., Philip H. Abbosh, Eric A. Ross, et al.. (2024). Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1). Journal of Clinical Oncology. 43(9). 1113–1122.
5.
Handorf, Elizabeth A., Pooja Ghatalia, Benjamin Miron, et al.. (2024). Survival Outcomes in Patients With Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Chemotherapy Stratified by Number of Cycles. Clinical Genitourinary Cancer. 22(6). 102218–102218.
6.
Wei, Shuanzeng, Daniel M. Geynisman, Andrew Elliott, et al.. (2023). Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma: A Comparative Study With Papillary and Clear Cell Renal Cell Carcinomas. Modern Pathology. 37(2). 100404–100404.
7.
Kutikov, Alexander, et al.. (2023). Between the Hammer and Anvil: Resolution of unresectable muscle invasive bladder cancer in a renal transplant patient after cessation of immunosuppressive therapy. Urology Case Reports. 48. 102399–102399.
8.
Handorf, Elizabeth A., Pooja Ghatalia, Benjamin Miron, et al.. (2023). Survival outcomes in patients with muscle-invasive bladder cancer receiving neoadjuvant chemotherapy stratified by number of cycles.. Journal of Clinical Oncology. 41(16_suppl). 4586–4586.
9.
Joyce, Daniel, Kevin Wymer, Vidit Sharma, et al.. (2022). Comparative cost‐effectiveness of neoadjuvant chemotherapy regimens for muscle‐invasive bladder cancer: Results according to VESPER data. Cancer. 128(24). 4194–4202.
10.
Bilušić, Marijo, Renee N. Donahue, Susan Wróblewski, et al.. (2022). A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). Prostate Cancer and Prostatic Diseases. 25(4). 735–740.
11.
McGregor, Bradley A., Daniel M. Geynisman, Mauricio Burotto, et al.. (2022). Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma. The Oncologist. 28(1). 72–79.
12.
Deng, Mengying, Elizabeth Handorf, Jonathan J. Paly, et al.. (2021). Early Prostate-Specific Antigen Kinetics for Low- and Intermediate-Risk Prostate Cancer Treated With Definitive Radiation Therapy. Practical Radiation Oncology. 12(1). 60–67.
13.
McGregor, Bradley A., Daniel M. Geynisman, Mauricio Burotto, et al.. (2021). PCN53 Grade 3/4 Adverse Event (AE) Costs of Nivolumab Plus Ipilimumab (N+I) Versus Nivolumab Plus Cabozantinib (N+C) and Pembrolizumab Plus Axitinib (P+A) for Previously Untreated Advanced Renal Cell Carcinoma (aRCC). Value in Health. 24. S28–S29.
14.
Geynisman, Daniel M., Bradley A. McGregor, Mauricio Burotto, et al.. (2021). PCN92 Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib (N+C) Versus Sunitinib (S) for Previously Untreated Advanced Renal Cell Carcinoma (aRCC). Value in Health. 24. S36–S36.
15.
Bass, Sarah Bauerle, et al.. (2020). Comparing Perceptions and Decisional Conflict Towards Participation in Cancer Clinical Trials Among African American Patients Who Have and Have Not Participated. Journal of Cancer Education. 37(2). 395–404.
16.
Cahn, David, Benjamin T. Ristau, Eric Ghiraldi, et al.. (2016). Bladder Preservation Therapy: A Review of the Literature and Future Directions. Urology. 96. 54–61.
17.
Nadal, Rosa, A. Amin, Daniel M. Geynisman, et al.. (2016). Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. Annals of Oncology. 27(7). 1304–1311.
18.
Necchi, Andrea, Gregory R. Pond, Daniele Raggi, et al.. (2016). Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis. Annals of Oncology. 27. vi291–vi291.
19.
Ghatalia, Pooja, Samuel Litwin, Eric M. Horwitz, et al.. (2016). Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review. Clinical Genitourinary Cancer. 15(3). e337–e343.
20.
Geynisman, Daniel M., Yuanyuan Zha, Rangesh Kunnavakkam, et al.. (2013). A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma. Journal for ImmunoTherapy of Cancer. 1(1). 8–8.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Efrat Dotan Breakdown of academic impact, for papers by Brian A. Costello Breakdown of academic impact, for papers by Arya Amini Breakdown of academic impact, for papers by Jamie Ritchey Breakdown of academic impact, for papers by Scott Ernst Breakdown of academic impact, for papers by Thenappan Chandrasekar Breakdown of academic impact, for papers by Matthew A. Powell Breakdown of academic impact, for papers by D. Hölzel Breakdown of academic impact, for papers by A. Karim Kader Breakdown of academic impact, for papers by Björn Tavelin